Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Amylyx Pharmaceuticals' cash burn relative to its market cap was relatively promising. One real positive is that analysts are forecasting that the company will reach breakeven. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about Amylyx Pharmaceuticals' situation. Taking an in-depth view of risks, we've identified 1 warning sign for Amylyx Pharmaceuticals that you should be aware of before investing.